Voyager Therapeutics develops life-changing gene therapies for severe diseases of the central nervous system (CNS) from discovery, preclinical and clinical development, through to commercialization. We focus on people suffering from devastating CNS diseases that lack safe and effective treatment options, particularly in the areas of advanced Parkinson’s disease, monogenic forms of amyotrophic lateral sclerosis (ALS), Friedreich’s ataxia, Huntington’s disease, frontotemporal dementia and Alzheimer’s disease, and severe, chronic pain.
Voyager’s mission is to develop and deliver life-changing therapies to people around the world affected by devastating diseases of the central nervous system. This begins with a commitment to discovery, research, development and manufacturing, and extends to our engagement with patients, healthcare providers, caregivers and advocacy organizations.
Voyager innovates and invests in novel adeno-associated virus (AAV) vector engineering and optimization, manufacturing that includes a baculovirus production system for producing AAV vectors at scale in insect-derived cells, and dosing that includes intraparenchymal, intrathecal and intravenous delivery techniques.
Our management team and founders represent some of the most esteemed scientific and clinical leaders in the fields of AAV gene therapy, expressed RNA interference, neuroscience preclinical and clinical development, and manufacturing.
We have broad strategic collaborations with Genzyme, a Sanofi company, and the University of Massachusetts Medical School (UMMS). We have also entered into license and other agreements with UMMS, the University of California San Francisco and Stanford University to access relevant technology and data.
We actively seek collaborators and licensing opportunities to explore certain programs, geographies and technologies.